- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03997851
Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects
March 22, 2021 updated by: Gil Yosipovitch, University of Miami
Currently, topical antihistamines and corticosteroids are mainly used for itching relief.
However, the over the counter antihistamines are not effective on all itch conditions.
Acetaminophen is a popular and widely used OTC drug for pain relief.
Although its mode of action is still unknown, recent studies have shown that acetaminophen indirectly activates cannabinoid CB1 receptors.
Recent studies have shown that topical cannabinoid agonists are effective for itch relief, the efficacy of topical acetaminophen will be tested for non-histaminergic itch relief.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a single-blinded, vehicle-controlled randomized study in healthy controls to test the efficacy of the topical gel formulation with three differing concentrations of acetaminophen (APAP) for itch relief.
To detect medium effects of the treatments with a given α of 0.5 and an error probability of 0.05, with a power of 0.95, the number of participants needed is 36 (10 within post hoc pairwise comparisons).
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy subjects must be between 18 and 50 years of age.
- Must be in general good health with no disease or physical conditions that would impair evaluation of itch and pain perception.
- No history of chronic itch or pain.
- Must abstain from the use of any systemic or topical anti-histamine, steroid, or pain relief medications from the week prior to the study till the completion of the study.
- Must abstain from the use of moisturizers on the arms 24 hours before study visits.
Exclusion Criteria:
- Individuals under 18 or over 50 years of age.
- Inability to complete the required measures.
- The presence of an itchy skin disease.
- Diagnosis of diseased that would affect itch or pain perception (e.g. neuropathies).
- Currently enrolled in any investigational study in which the subject is receiving any type of drug, biological, or non-drug therapy.
- Use of oral, topical analgesics, or other medications known to interfere with itch or pain perception in the week prior to the study and throughout the study (e.g. antihistamines, anesthetics, opioids, neuroleptics, etc.).
- Use of emollients on the arms a week prior to the study and throughout the study.
- Known allergies to acetaminophen and cowhage.
- Pregnant women. (Women of child bearing potential will undergo an hCG pregnancy test).
- Currently incarcerated.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Topical 5% acetaminophen gel
Topical 5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits.
The gel will be applied to the test area and will be allowed 30 minutes to adsorb.
Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
|
Topical acetaminophen gel
Other Names:
|
EXPERIMENTAL: Topical 2.5% acetaminophen gel
Topical 2.5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits.
The gel will be applied to the test area and will be allowed 30 minutes to adsorb.
Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
|
Topical acetaminophen gel
Other Names:
|
EXPERIMENTAL: Topical 1% acetaminophen gel
Topical 1% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits.
The gel will be applied to the test area and will be allowed 30 minutes to adsorb.
Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
|
Topical acetaminophen gel
Other Names:
|
PLACEBO_COMPARATOR: Topical vehicle gel
Topical vehile gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits.
The gel will be applied to the test area and will be allowed 30 minutes to adsorb.
Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
|
Topical vehicle gel
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Itch Intensity Between the Vehicle and Active Treatments During Non-histaminergic Itch Induction
Time Frame: 10 minutes
|
Peak itch intensity between the vehicle and 3 other active treatments (5%, 2.5%, and 1% acetaminophen gels) after non-histaminergic itch induction (cowhage).
Itch intensity was measured on a 10cm scale visual analog scale for 10 minutes.
0 was weighted with "no itch" and 10 was weighted with "most itch imaginable".
|
10 minutes
|
Peak Itch Intensity Between the Vehicle and Active Treatments During Histaminergic Itch Induction
Time Frame: 10 minutes
|
Peak itch intensity between the vehicle and 3 other active treatments (5%, 2.5%, and 1% acetaminophen gels) after histaminergic itch induction.
Itch intensity was measured on a 10cm scale visual analog scale for 10 minutes.
0 was weighted with "no itch" and 10 was weighted with "most itch imaginable".
|
10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thermal Threshold Detection (Heat Pain)
Time Frame: 3 minutes
|
Standardized quantitative sensory testing is performed to measure heat pain threshold (assesses the threshold at which heat pain sensation is first detected).
Measured in Celsius.
|
3 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 22, 2019
Primary Completion (ACTUAL)
March 18, 2020
Study Completion (ACTUAL)
March 18, 2020
Study Registration Dates
First Submitted
June 24, 2019
First Submitted That Met QC Criteria
June 24, 2019
First Posted (ACTUAL)
June 25, 2019
Study Record Updates
Last Update Posted (ACTUAL)
April 19, 2021
Last Update Submitted That Met QC Criteria
March 22, 2021
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20190133
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pruritus
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Toray Industries, IncCompletedUremic PruritusBulgaria, Germany
-
Cara Therapeutics, Inc.CompletedPruritus | Uremic PruritusUnited States
-
Thammasat University HospitalCompletedUremic PruritusThailand
-
Conmed Pharmaceutical & Bio-Medical CorporationChang Gung Memorial Hospital; Kaohsiung Medical University; Tri-Service General... and other collaboratorsCompleted
-
Haisco Pharmaceutical Group Co., Ltd.Completed
-
Kissei Pharmaceutical Co., Ltd.Maruishi PharmaceuticalCompleted
-
Chang Gung Memorial HospitalUnknown
-
Lumosa Therapeutics Co., Ltd.Unknown
-
RDD Pharma LtdWithdrawn
Clinical Trials on Acetaminophen
-
Massachusetts General HospitalCompletedPain, Postoperative | Infertility, FemaleUnited States
-
Kaveh Aslani, MDCompletedAirway Obstruction | Tonsillitis | Difficulty SwallowingUnited States
-
Taipei Medical University WanFang HospitalUnknownCervical Radiculopathy | Radicular Pain | Acute Neck Pain | Cervicobrachial PainTaiwan
-
Medical University of South CarolinaCompletedPain, PostoperativeUnited States
-
MallinckrodtTerminatedAcute Pain, PostoperativeUnited States
-
Duke UniversityCompletedOsteoarthritis | Acetaminophen | Arthroplasty, Hip ReplacementUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Spectrum Health HospitalsTerminatedHip FractureUnited States
-
Babiash, Kimberly H., M.D.Unknown
-
University of UtahCompletedPost-operative Craniotomy Patients | Carotid Endarterectomy and Carotid Artery Stenosis Patients | Post-op Spine Patients Admitted to the NCCU | Endovascular Patients Undergoing Intracranial Intervention | Traumatic Brain Injuries NPO for at Least 12 HoursUnited States